Aggregate analyst targets are a good starting point: All reputable analysts with $4aud+ (MESO / 5 / aud/USD = MSB) and very conservatively in general, only pricing in agvhd, heart failure and chronic back pain treatments, minimal/no extensions of these priced in, and others pipelines priced in at all e.g. chrohns), yet, well... you can see where we are trading.
A universe of IPs under our belt, years of experience bashing heads with the FDA, and comprehensive strategic and manufacturing strategies in place. Of course anyone has alot of reading to do to maintain a certain level of conviction in MSB, but personally, as far as I'm concerned, on the info to date, anything under $3 is a steal.
Highly recommend most recent webcast/investor call available on the mesoblast website, even though this was also pre-covid initiatives, the professor gives a good overview of the company and where they are at.
Big few months coming up: potential first FDA approved product for agvhd, and stage 3 read outs for blockbuster product's, and basically a premium-free call style option for covid treatment re ARDS. Good luck!
MSB Price at posting:
$2.03 Sentiment: Buy Disclosure: Held
(20min delay)